-
Featured Authors
-
Archives
- May 2013
- April 2013
- March 2013
- February 2013
- January 2013
- December 2012
- November 2012
- October 2012
- September 2012
- August 2012
- July 2012
- June 2012
- May 2012
- April 2012
- March 2012
- February 2012
- January 2012
- December 2011
- November 2011
- October 2011
- September 2011
- August 2011
- July 2011
- June 2011
- May 2011
- April 2011
- March 2011
- February 2011
- January 2011
- December 2010
- November 2010
- October 2010
- September 2010
- August 2010
- July 2010
- June 2010
- May 2010
- April 2010
- March 2010
- February 2010
- January 2010
- December 2009
- November 2009
- October 2009
- September 2009
- August 2009
- July 2009
- June 2009
- May 2009
- April 2009
- March 2009
- February 2009
- January 2009
- December 2008
- November 2008
- October 2008
- September 2008
- August 2008
- July 2008
- June 2008
- May 2008
- April 2008
- March 2008
- February 2008
-
Meta
Tag Archives: Biotechnology Industry Organization
2011 BIO International Convention Super Sessions
2011 BIO International Convention Super Sessions Focus on State of the Industry C-Level speakers lead broad conversations on global biotech, industry forecast, and key trends WASHINGTON, D.C. (March 2, 2011) — The 2011 BIO International Convention will feature six high-level super sessions focused on the state of the industry, global biotech advancements and the outlook on the future of the industry. Hosted by the Biotechnology Industry Organization (BIO), the global event for biotechnology will take Read More >
Patently BIOtech
Leave a comment
Email This Post
Tags: BIO, BIO International Convention, Bio-Innovation Scorecard, Biologics, biotechnology, Biotechnology Industry Organization, Biotechnology Industry Report, Biotechnology Innovation Ecosystem, Biotechnology Trade Expo, Burrill, Campbell Alliance, Dealmakers' Intentions, Eli Lilly and Company, emerging markets, Ernst & Young, Fareed Zakaria, global biotech, Jim Greenwood, Merck, Scientific American, State-of-the-Industry Report, Super Sessions
Tags: BIO, BIO International Convention, Bio-Innovation Scorecard, Biologics, biotechnology, Biotechnology Industry Organization, Biotechnology Industry Report, Biotechnology Innovation Ecosystem, Biotechnology Trade Expo, Burrill, Campbell Alliance, Dealmakers' Intentions, Eli Lilly and Company, emerging markets, Ernst & Young, Fareed Zakaria, global biotech, Jim Greenwood, Merck, Scientific American, State-of-the-Industry Report, Super Sessions
BIO Comments to USTR on 2011 Special 301 Review
BIO Comments to USTR on 2011 Special 301 Review (February 15, 2011) In comments to the U.S. Trade Representative (USTR), BIO stresses the critical importance of protecting intellectual property abroad and made recommendations about which countries to include on the Priority Watch and Watch List, which to elevate as a Priority Foreigh Country, and which countries to monitor. Read the Comments (link to http://bio.org/pdfs/BIO_2011_Special_301_Submission.pdf) Read the Press Release (link to http://bio.org/news/pressreleases/newsitem.asp?id=2011_0221_01)
BIO’s Intellectual Property Counsels’ Committee Spring Conference and Meeting: Seattle
Over the past eight years, BIO’s semiannual IP Counsels Committee Conference has become a popular and growing event among our members’ IP and legal professionals. Our upcoming 2011 Spring IPCC Conference in Seattle, WA on April 13-15 will be an excellent opportunity for IP professionals to hear, listen, and learn about current and projected topics related to biotechnology IP. We invite you to join us in an informal, fun and informative setting to meet fellow in-house Read More >
Patently BIOtech
Leave a comment
Email This Post
Tags: BIO, biosimilars, biotechnology, Biotechnology Industry Organization, double patenting, emerging markets, Ethics for In-House IP Attorneys, Intellectual Property, Intellectual Property Counsels' Committee, IP Counsels' Committee, IPCC, Myriad, Seattle, Stanford v. Roche
Tags: BIO, biosimilars, biotechnology, Biotechnology Industry Organization, double patenting, emerging markets, Ethics for In-House IP Attorneys, Intellectual Property, Intellectual Property Counsels' Committee, IP Counsels' Committee, IPCC, Myriad, Seattle, Stanford v. Roche
BIO’s IP Priorities for 2011
As we start a new year, the BIO Intellectual Property Department has determined their 2011 priorities. Intellectual Property remains a foundational priority for BIO and our 1100 biotechnology company members. BIO’s IP department has approved the following priorities for 2011: 1) PTO reforms to improve efficient, timely and quality examination 2) Congressional patent reform legislation 3) Improving IP protection in key foreign markets 4) IP legal developments in the courts 5) Protecting the breadth and flexibility of the patent Read More >
Patently BIOtech
Leave a comment
Email This Post
Tags: Bayh-Dole, BIO, Biotechnology Industry Organization, economic development, Intellectual Property, International, IP, Patent Reform, patent reform in foreign markets, patents, Supreme Court, Technology Transfer, Technology Transfer, United States Patent and Trademark Office
Tags: Bayh-Dole, BIO, Biotechnology Industry Organization, economic development, Intellectual Property, International, IP, Patent Reform, patent reform in foreign markets, patents, Supreme Court, Technology Transfer, Technology Transfer, United States Patent and Trademark Office
BIO’s Comments on proposed PTO Humanitarian Technologies and Licensing Through the Intellectual Property System
Here are the highlights from BIO’s recent submission on the proposed PTO “Request for Comments on Incentivizing Humanitarian Technologies and Licensing Through the Intellectual Property System.” Background: 1. “BIO’s members also understand that problems with access to medicines and other biotechnology products in the developing world have very little to do with the patent system, and are generally caused by other factors outside the control of individual stakeholders, such as lack of adequate local manufacturing, Read More >
Patently BIOtech
1 Comment
Email This Post
Tags: access to medicines, BIO, BIOTECH, biotechnology, Biotechnology Industry Organization, developing countries, economic development, Global Health, Green Technology, humanitarian, humanitarian technologies, International, Patent and Trademark Office, Patent Reform, patents, poverty, PTO, re-examination vouchers, U.S. Patent and Trademark Office, United States Patent and Trademark Office, USPTO
Tags: access to medicines, BIO, BIOTECH, biotechnology, Biotechnology Industry Organization, developing countries, economic development, Global Health, Green Technology, humanitarian, humanitarian technologies, International, Patent and Trademark Office, Patent Reform, patents, poverty, PTO, re-examination vouchers, U.S. Patent and Trademark Office, United States Patent and Trademark Office, USPTO
